Related Experiment Video

Updated: Oct 2, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants

Almu'atasim Khamees1, Jamal Bani-Issa1, Mazhar Salim Al Zoubi2

  • 1Department of Clinical Sciences, Faculty of Medicine, Yarmouk University, Irbid 211-63, Jordan.

Pathogens (Basel, Switzerland)
|February 26, 2022
PubMed

Insights

This review explores COVID-19 treatments, vaccines, and emerging variants. It questions the effectiveness of current prevention measures against the persistent pandemic and its new strains.

Area of Science:

  • Virology
  • Epidemiology
  • Public Health

Background:

  • COVID-19, caused by the novel coronavirus (2019-nCoV), emerged in 2019, leading to a global pandemic.
  • High transmissibility and severe morbidity/mortality rates necessitate continuous research, especially in vulnerable populations with chronic conditions.
  • Emerging polymorphic variants of 2019-nCoV underscore the urgent need for effective vaccination strategies.

Purpose of the Study:

  • To review recent advancements in COVID-19 treatment and vaccination.
  • To analyze the characteristics of newly emerging 2019-nCoV variants.
  • To discuss potential mitigation strategies for the ongoing pandemic.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of data on COVID-19 treatment efficacy and vaccine development.
  • Examination of genomic surveillance data for emerging viral variants.

Main Results:

  • Multiple treatment options and over 25 vaccines are in development.
  • Periodic oscillations in infection peaks raise concerns about the efficacy of current prevention strategies.
  • New variants continue to emerge globally, posing challenges to control efforts.

Conclusions:

  • Ongoing research into treatments and vaccines is crucial for managing COVID-19.
  • The emergence of new variants necessitates adaptive strategies and reassessed prevention measures.
  • Understanding and mitigating the impact of this aggressive pandemic remains a global priority.
Keywords:
2019-nCoVCOVID-19pandemicvaccinesvariants

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.4K
Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.4K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
542
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
482
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.6K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
259
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
34.2K